Novavax, Inc. (NVAX)
- Previous Close
3.8900 - Open
3.8900 - Bid 3.9700 x 1800
- Ask 4.0000 x 1800
- Day's Range
3.8600 - 4.0199 - 52 Week Range
3.5300 - 11.3600 - Volume
2,900,400 - Avg. Volume
7,360,982 - Market Cap (intraday)
555.613M - Beta (5Y Monthly) 1.60
- PE Ratio (TTM)
-- - EPS (TTM)
-5.4100 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.40
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
www.novavax.comRecent News: NVAX
Performance Overview: NVAX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVAX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVAX
Valuation Measures
Market Cap
555.61M
Enterprise Value
216.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.72
Price/Book (mrq)
--
Enterprise Value/Revenue
0.39
Enterprise Value/EBITDA
-0.44
Financial Highlights
Profitability and Income Statement
Profit Margin
-55.41%
Return on Assets (ttm)
-17.02%
Return on Equity (ttm)
--
Revenue (ttm)
983.71M
Net Income Avi to Common (ttm)
-545.06M
Diluted EPS (ttm)
-5.4100
Balance Sheet and Cash Flow
Total Cash (mrq)
568.51M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-979.22M
Research Analysis: NVAX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell